VivoSeq
Infectious Disease

HIV Infections

31

Pipeline Programs↗

21

Active Trials↗

7

Companies Involved↗

HIV Infections is a moderately active landscape with 31 programs across 7 companies. The most active players are Bristol-Myers Squibb, Eli Lilly, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 1 therapy is approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

37/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1GSK logo

GSK

22 programs

Phase 3Gilead logo

Gilead

4 programs

ApprovedC

Center for Innovative Public Health Research

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

13 of 19 classified programs — the dominant modality here.

32%ALL OTHERSRNA therapy316%Monoclonal antibody211%Protein / enzyme15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 50% of 44 pipeline programs.

Analysis

Trial Status

28

clinical trials

Recruiting9 · 32%
Completed7 · 25%
Active, not recruiting7 · 25%
Not yet recruiting5 · 18%

Clinical Trials

Trial Activity

28 trials

A Multi-part, Phase 1, First-Time-in-Human Study to Investigate Safety, Tolerability, and PK of VH4770359 in Healthy Participants
Recruiting·GSK logoGSK·Phase 1·NCT07525544·214 enrolled
Long-acting HIV Pre-Exposure Prophylaxis Integrated With Community-based Sexual and Reproductive Health in South Africa (LAPIS): A Hybrid (1a) Cluster Randomised Controlled Phase 3B Trial of Effectiveness and Implementation
Recruiting·AAfrica Health Research Institute·Phase 3·NCT06250504·2,052 enrolled
Harnessing the Power of Text Messaging to Reduce HIV Incidence in Adolescent Males Across the United States
Recruiting·CCenter for Innovative Public Health Research·Preclinical·NCT06230367·5,000 enrolled
Dasatinib for HIV-1 Reservoir Reduction
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07342491·14 enrolled
A Phase 1, Open-Label, Single Dose Study to Assess the Absolute Bioavailability, Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]VH4524184 in Healthy Participants
Recruiting·GSK logoGSK·Phase 1·NCT07636928·9 enrolled
Texting in Community Health Center Dental Clinics to Reduce HIV Risk
Recruiting·BBoston University·Preclinical·NCT06088277·266 enrolled
A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single Ascending Dose and Multiple Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered VH4524184 in Healthy Adults
Recruiting·GSK logoGSK·Phase 1·NCT06310551·372 enrolled
Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)
Recruiting·Gilead logoGilead·N/A·NCT07473778·3,000 enrolled
An Effectiveness Trial of WINGS+PrEP: a Syndemic mHealth Intervention to Increase PrEP Uptake Among Women Impacted by Heavy Alcohol Use and Partner Violence in the Criminal Legal System
Recruiting·CColumbia University·Preclinical·NCT06853314·307 enrolled
Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV: The ANRS CO3 Aquitaine Cohort - AquiVIH-NA
Active, not recruiting·UUniversity Hospital, Bordeaux·N/A·NCT03296202·7,500 enrolled
An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1
Active, not recruiting·GSK logoGSK·Phase 1·NCT07053384·130 enrolled
Massachusetts HIV and Justice Involved Populations Research Network
Active, not recruiting·BBoston Medical Center·N/A·NCT06679751·59 enrolled
A Phase 1, Placebo-controlled, Blinded, Dose-escalation Study to Evaluate the Safety and Immunogenicity of mRNAs Encoding HIV Immunogens (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 gp151) in Adult Participants Without HIV and in Overall Good Health in South Africa.
Active, not recruiting·IInternational AIDS Vaccine Initiative·Phase 1·NCT06694753·96 enrolled
A Phase 1, Open-Label, Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VH4527079, Administered Either Intravenously or Subcutaneously to Healthy Adults and Persons With HIV
Active, not recruiting·GSK logoGSK·Phase 1·NCT06652958·102 enrolled
A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT03635788·456 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)